Loading organizations...
Sencure is an innovative startup developing IC technology for medical devices and health-tracking wearables. Our mission is to improve wearable devices by using less power while improving signal quality.
Sencure has raised $12.0M across 3 funding rounds.
Sencure has raised $12.0M in total across 3 funding rounds.
Sencure has raised $12.0M across 3 funding rounds. Most recently, it raised $4.0M Series B in March 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2025 | $4M Series B | — | Cottonwood Technology Fund | Announced |
| Jul 1, 2023 | $6M Series A | — | Cottonwood Technology Fund | Announced |
| Apr 1, 2021 | $2M Seed | — | Cottonwood Technology Fund | Announced |
Sencure has raised $12.0M in total across 3 funding rounds.
Sencure's investors include Cottonwood Technology Fund.
Sencure is a Dutch startup founded in 2021 that develops advanced biosensor chips for wearable health technology, focusing on low-power, high-precision measurements of electrophysiological signals like heart (ECG), brain (EEG), muscle (EMG), and breathing activity.[1][2][4] Its flagship SNCE800 chip integrates an analog front-end, ADC, and DSP into a single IC, enabling superior signal quality in medical patches, remote patient monitoring devices, and wellness wearables while minimizing power use and patient burden.[2][4] Sencure serves healthcare providers, medical device manufacturers, and consumer electronics firms by offering chips, evaluation kits, and design services that simplify compliance with regulations like MDR and IEC 60601-1.[2][3] The company has raised $11.46M in seed funding, with its latest $4.06M round three months ago, signaling strong growth momentum in the semiconductors and medtech sectors.[1]
Sencure emerged from ItoM Medical BV, established in 2018 as the medical arm of Semiconductor Ideas to the Market (ItoM) BV, a chip development firm.[1][5] This origin blended semiconductor expertise with medical device knowledge, uniting IC designers and electrophysiology specialists passionate about non-invasive bio-signal measurement.[5][6] Founded formally in 2021 and based in Roden (with operations in Enschede), Netherlands, Sencure rebranded to focus on bridging these worlds for wearable innovation.[1][5] A pivotal moment came in 2023 with a €5M raise to commercialize the SNCE800 chip, accelerating its shift from R&D to market-ready solutions for remote monitoring and diagnostics.[1]
Sencure rides the wearable medtech boom, fueled by rising demand for remote patient monitoring amid aging populations, chronic disease prevalence, and post-pandemic telehealth adoption.[1][5] Its timing aligns with advances in semiconductors enabling tiny, power-efficient sensors, addressing market pain points like bulky devices and poor accuracy in consumer and clinical wearables.[2][4] Favorable forces include EU MDR pushes for innovative compliance and growth in biosensors (part of a 7,342-company semiconductors ecosystem).[1][3] By partnering with device makers, Sencure influences the ecosystem as an enabler, powering next-gen applications like hospital diagnostics, asthma management (e.g., DIAMONDs project), and consumer health trackers, potentially expanding to brain-computer interfaces or AI-driven predictive health.[1][4]
Sencure is poised for scaling via deeper OEM partnerships and SNCE800 adoption, with recent funding supporting production ramp-up and new applications like textile-integrated sensors.[1][4] Trends like AI-enhanced signal processing and edge computing in wearables will amplify its edge, while global medtech deregulation could unlock U.S./Asia markets.[2][3] Its influence may evolve from chip supplier to ecosystem orchestrator, driving ubiquitous, unobtrusive health monitoring that transforms patient compliance into proactive care—echoing its mission to revolutionize tracking with minimal burden.[3][5]
